Josef H. Von Rickenbach

Josef von Rickenbach is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm’s Life Sciences investing team as part of its broader Healthcare sector, and currently serves as the Managing Director of stet vision LLC as well.

Previously, Joe was the Co-Founder, President, and CEO of biotechnology company Helio Vision, Inc., a Boston-based ophthalmic biopharma company developing a therapy for proliferative vitreoretinopathy. Helio Vision, Inc. was merged with Aldeyra, Inc. (NASDAQ: ALDX) in 2019. Prior to that, Joe was also the Co-Founder, Chairman, and CEO of PAREXEL International Corporation, leading the company in its growth from one of the first clinical research organizations in the early 1980s to its place as a leading global biopharmaceutical services provider, including its IPO, multiple secondary offerings, and over 40 mergers & acquisitions during his 36-year tenure. After beginning his career with Schering-Plough, he held positions with ENSECO (formerly ERCO).

Joe was named Executive of the Year in North America in the 2010 International Business Awards In 2013 and has been honored by the Massachusetts Biotechnology Council with the Henri Termeer Innovative Leadership Award. In 2014, he was named Immigrant Entrepreneur of the Year in Life Sciences. In 2018, he received the Scrip Informa Lifetime Achievement Award and was awarded the Ellis Island Medal of Honor.

Joe is currently a member of the Health Policy and Management Executive Council of the Harvard T.H. Chan School of Public Health and serves on the Board of Trustees for McLean Hospital. Chairman of ZAGENO, he also serves as a Board Member for the Network of Excellence in Health Innovation and Aileron Therapeutics. Joe received his B.A. in Business Economics from Lucerne University before earning his M.B.A from Harvard Business School.